SEARCH

SEARCH BY CITATION

References

  • 1
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296305.
  • 2
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 70514.
  • 3
    Hilsabeck RC, Hassanein TI, Perry W. Biopsychosocial predictors of fatigue in chronic hepatitis C. J Psychosom Res 2005; 58: 1738.
  • 4
    Teuber G, Schäfer A, Rimpel J, et al. Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: association with demographic factors, inflammatory activity, and degree of fibrosis. J Hepatol 2008; 49: 9239.
  • 5
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790800.
  • 6
    Strauss E, Teixeira MC. Quality of life in hepatitis C. Liver Int 2006; 26: 75565.
  • 7
    Bonkovsky HL, Woolley JM, the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 26470.
  • 8
    Hoofnagle JH, Di Bisceglie AM. Drug therapy: the treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 34756.
  • 9
    Córdoba J, Flavià M, Jacas C, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 2318.
  • 10
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 7048.
  • 11
    Fontana RJ, Moyer CA, Sonnad S, et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001; 96: 1708.
    Direct Link:
  • 12
    Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 25319.
  • 13
    Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 295303.
  • 14
    Gutteling JJ, De Man RA, Busschbach JJ, Darlington AS. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007; 65: 22734.
  • 15
    Häuser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2004; 2: 15763.
  • 16
    Quarantini LC, Miranda-Scippa A, Batista-Neves S, et al. The effect of early virological response in health-related quality of life in HCV-infected patients. J Med Virol 2008; 80: 41923.
  • 17
    Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kD) (Pegasys) improves HR-QOL outcomes compared with unmodified interferon alpha-2a (Roferon-A) in patient with chronic hepatitis C. Pharmacoeconomics 2003; 21: 3419.
  • 18
    Mathew A, Peiffer LP, Rhoades K, McGarrity TJ. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha-2b and ribavirin. Health Qual Life Outcomes 2006; 12: 30.
  • 19
    Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005; 11: 74948.
  • 20
    Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006; 41: 57785.
  • 21
    Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 67581.
  • 22
    Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 42031.
  • 23
    Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection. Results of quality of life. Dig Dis Sci 1996; 41: 75S80S.
  • 24
    Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 33443.
  • 25
    Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok ASF. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002; 36: 4358.
  • 26
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 20912.
  • 27
    Häuser W, Zimmer C, Schiedermaier P, Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004; 66: 9548.
  • 28
    Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 24826.
  • 29
    Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok ASF. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 273744.
    Direct Link:
  • 30
    McHutchison J, Ware JE Jr, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 1407.
  • 31
    Neary MP, Cort S, Bayliss MS, Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19(Suppl 1): 7785.
  • 32
    Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11: 15765.
  • 33
    Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002; 32: 110.
  • 34
    Helbling B, Overbeck K, Gonvers JJ, et al. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57: 1597603.
  • 35
    Arora S, O’Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006; 21: 40612.
  • 36
    Danoff A, Khan O, Wan DW, et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol 2006; 101: 123543.
    Direct Link:
  • 37
    Dove LM, Rosen RC, Ramcharran D, et al. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology 2009; 137: 87384, 884.e1.
  • 38
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 242941.
  • 39
    Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 47292.
  • 40
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 6969.
  • 41
    Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 101523.
  • 42
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, R W. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 6469.
  • 43
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
  • 44
    Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: A User’s Manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
  • 45
    Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 28: 6674.
  • 46
    Vonesh E, Chinchilli V, Pu K. Goodness-of-fit in generalized nonlinear mixed-effects models. Biometrics 1996; 52: 57287.
  • 47
    Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45: 115463.
  • 48
    Kanwal F, Gralnek IM, Hays R, et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol 2009; 7: 7939.